Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
6,151 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05731258 | Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen | recruiting | — | 150 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05722275 | Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics | recruiting | — | 400 | Chinese Academy of SciencesOTHER_GOV | 2 | Feb 14, 2023 |
| clinicaltrials |
| NCT05722392 | Safety and Efficacy of Two-step Radical Prostatectomy | recruiting | — | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05501353 | Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods | recruiting | — | 125 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05717790 | Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma | recruiting | N/A | 288 | Fourth Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05718492 | A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents | recruiting | N/A | 100 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05713578 | Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study | recruiting | Early Phase 1 | 220 | Qilu Hospital of Shandong UniversityOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05707819 | Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | recruiting | — | 43 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05433935 | Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas | recruiting | — | 5,000 | Zhejiang UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05692674 | A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction | recruiting | Phase 2 | 67 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05690802 | The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV(TSEPHCC) | recruiting | N/A | 1,060 | Xijing HospitalOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05686434 | Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) | recruiting | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05367700 | A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. | recruiting | Phase 1 | 108 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 13, 2023 | clinicaltrials |
| NCT05682131 | South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol(SCCCG-R-ALL) | recruiting | Phase 4 | 210 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05682755 | Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT | recruiting | Phase 1 / Phase 2 | 77 | Sichuan UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05674305 | Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy | recruiting | Phase 3 | 366 | Fudan UniversityOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05676190 | Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer | recruiting | N/A | 80 | ShiCang YuOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05672043 | Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China(GRIPP) | recruiting | — | 400 | Beijing Tiantan HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05236972 | PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer | recruiting | Phase 3 | 323 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2022 | clinicaltrials |
| NCT05661786 | Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase(PILOT) | recruiting | — | 4,500 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05659628 | CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL | recruiting | Phase 1 | 24 | Ningbo No. 1 HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05636605 | Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy | recruiting | — | 200 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05252078 | Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients(ALTER-E005) | recruiting | Phase 2 | 30 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05651672 | Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations | recruiting | Phase 2 | 100 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05652192 | SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC | recruiting | Phase 2 | 37 | Zhejiang Cancer HospitalOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05429463 | Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ)(neoSCORE Ⅱ) | recruiting | Phase 3 | 250 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05476432 | HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study | recruiting | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05594797 | Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM | recruiting | Phase 2 | 100 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05000892 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms | recruiting | Phase 2 | 15 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05628922 | Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT | recruiting | Phase 2 | 198 | Fudan UniversityOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT03587480 | Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy(TELEPHOME) | recruiting | N/A | 250 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05626400 | Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL | recruiting | N/A | 100 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05620693 | Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05620706 | Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05620732 | Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05620680 | CD7 CAR-T Cells in T-cell Lymphoma/Leukemia | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT04451473 | Lung Surgery With Enhanced Recovery VS. Lung Surgery Without Enhanced Recovery | recruiting | N/A | 350 | The Second Hospital of Shandong UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT04688801 | Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer | recruiting | N/A | 200 | The Second Hospital of Shandong UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05528484 | Self-reported Outcomes of Patients in ERAS Nursing | recruiting | N/A | 600 | The Second Hospital of Shandong UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05618821 | Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer | recruiting | Phase 2 | 68 | Fujian Medical UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05315895 | The Dampness Syndrome of Chinese Medicine Cohort Study(DACOS) | recruiting | — | 100,000 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT04078230 | Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma | recruiting | N/A | 168 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 2 | Nov 9, 2022 | clinicaltrials |
| NCT05600660 | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 28 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05608213 | Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC | recruiting | Phase 3 | 187 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04922567 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 289 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05607329 | Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial | recruiting | N/A | 400 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05603078 | A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)(BIRKIN) | recruiting | N/A | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05595590 | Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05579353 | The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer | recruiting | — | 200 | Jingbo ChenOTHER | 1 | Oct 13, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials